VivoSeq
Other

Aging

0

Pipeline Programs

9

Active Trials

1

Companies Involved

Aging is an early-stage landscape with 0 programs across 1 company. The most active players are Università degli Studi di Trento.

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

37

clinical trials

Completed18 · 49%
Unknown status6 · 16%
Recruiting5 · 14%
Withdrawn3 · 8%
Not yet recruiting3 · 8%
Enrolling by invitation1 · 3%
Other1 · 3%

Trial Activity

37 trials

Pilot fMRI Studies of Aging-Related Effects of THC
Recruiting·YYale University·Phase 2·NCT06647524·10 enrolled
MIBG in Aging and Neurologic Disorders
Enrolling by invitation·MMayo Clinic·Phase 4·NCT05514106·50 enrolled
Latent Aging Mechanisms in Pain and Sleep
Completed·UUniversity of Florida·Phase 2·NCT04683640·33 enrolled
Sex, Aging and Antiretroviral Pharmacokinetics
Completed··N/A·NCT00666055·11 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)